All In MedTech

FDA Clearance Tracker · P180027

Flow Re-Direction Endoluminal Device (FRED®) System

Premarket approval (PMA) is the pathway for the highest-risk devices. FDA reviews clinical evidence of safety and effectiveness before approving.

Last checked: Nov 20, 2026Latest source record: Dec 16, 2019 (this decision)Source: openFDAMethods & limitations

PMA

Decided

Dec 16, 2019

Approved

Time to decision

502 days

Received Aug 1, 2018. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA

Device class

Class III

The decision

FDA number
P180027
Device name
Flow Re-Direction Endoluminal Device (FRED®) System
Applicant location
Aliso Viejo, CA
Received
Aug 1, 2018
Decided
Dec 16, 2019
Decision
Approved
Supplements
13 in FDA's data for this PMA. See them on the FDA record

Device type

Device class
Class III

Every decision under product code OUT

FDA's approval statement

As written in FDA's record.

Approval for The Flow Re-Direction Endoluminal Device (FRED®) System. The Flow Re-Direction Endoluminal Device (FRED®) System is indicated for use in the internal carotid artery from the petrous segment to the terminus for the endovascular treatment of adult patients (22 years of age or older) with wide-necked (neck width >= 4 mm or dome-to-neck ratio < 2) saccular or fusiform intracranial aneurysms arising from a parent vessel with a diameter >= 2.0 mm and <= 5.0 mm.

How new is this?

These are facts about FDA's records. They are not a judgment about the device.

  • It is not the first decision under product code OUT. The earliest in FDA's data is P100018, decided Apr 6, 2011.
  • It is not on FDA's public list of Breakthrough Devices with marketing authorization (list dated June 30, 2026). FDA does not publish which devices hold the designation before they are authorized, and the list is updated only a few times a year.

Source documents

Other decisions for MicroVention, Inc.

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

5 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.